• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (52)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Neurology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Ville Leinonen, MD, PhD; Irina Alafuzoff, MD, PhD; Sargo Aalto, MSc; Timo Suotunen, BM; Sakari Savolainen, MD, PhD; Kjell Någren, PhD; Tero Tapiola, MD, PhD; Tuula Pirttilä, MD, PhD; Jaakko Rinne, MD, PhD; Juha E. Jääskeläinen, MD, PhD; Hilkka Soininen, MD, PhD; Juha O. Rinne, MD, PhD

Arch Neurol. 2008;65(10):1304-1309.

Objective  To compare carbon 11–labeled Pittsburgh Compound B ([¹¹C]PiB) positron emission tomography (PET) findings in patients with and without Alzheimer disease lesions in frontal cortical biopsy specimens.

Design  Cross-sectional study of [¹¹C]PiB PET findings in patients with or without β-amyloid (Aβ) aggregates in frontal cortical biopsy specimens.

Setting  Two university hospitals in Finland.

Patients  Ten patients who had undergone intraventricular pressure monitoring with a frontal cortical biopsy (evaluated for Aβ aggregates and hyperphosphorylated tau) for suspected normal-pressure hydrocephalus.

Interventions  [¹¹C]PiB PET and evaluation for cognitive impairment using a battery of neuropsychological tests.

Main Outcome Measures  Immunohistochemical evaluation for Aβ aggregates and hyperphosphorylated tau in the frontal cortical biopsy specimen and [¹¹C]PiB PET.

Results  In patients with Aβ aggregates in the frontal cortical biopsy specimen, PET imaging revealed higher [¹¹C]PiB uptake (P < .05) in the frontal, parietal, and lateral temporal cortices and in the striatum as compared with the patients without frontal Aβ deposits.

Conclusions  Our study supports the use of noninvasive [¹¹C]PiB PET in the assessment of Aβ deposition in the brain. Large prospective studies are required to verify whether [¹¹C]PiB PET will be a diagnostic aid, particularly in early Alzheimer disease.

Author Affiliations: Departments of Neurosurgery (Drs Leinonen, Savolainen, J. Rinne, and Jääskeläinen) and Neurology (Drs Tapiola, Pirttilä, and Soininen), Kuopio University Hospital and Unit of Pathology and Neurology, Department of Clinical Medicine (Dr Alafuzoff), and Unit of Neurology, Institute of Clinical Medicine (Drs Pirttilä and Soininen), University of Kuopio, Kuopio and Turku PET Centre, University of Turku, Turku (Drs Någren and J. O. Rinne and Messrs Aalto and Suotunen), Finland.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

This Month in Archives of Neurology
Arch Neurol. 2008;65(10):1278-1280.
FULL TEXT  

Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist
William E. Klunk
Arch Neurol. 2008;65(10):1281-1283.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Brain Amyloid Imaging
Rowe and Villemagne
JNM 2011;52:1733-1740.
ABSTRACT | FULL TEXT  

Amyloid Imaging: Liberal or Conservative? Let the Data Decide
Jagust
Arch Neurol 2011;68:1377-1378.
FULL TEXT  

Association Between In Vivo Fluorine 18-Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology
Wolk et al.
Arch Neurol 2011;68:1398-1403.
ABSTRACT | FULL TEXT  

Human apoE Isoforms Differentially Regulate Brain Amyloid-{beta} Peptide Clearance
Castellano et al.
Sci Transl Med 2011;3:89ra57-89ra57.
ABSTRACT | FULL TEXT  

In Vivo Fibrillar {beta}-Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults
Sojkova et al.
Arch Neurol 2011;68:232-240.
ABSTRACT | FULL TEXT  

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
Kadir et al.
Brain 2011;134:301-317.
ABSTRACT | FULL TEXT  

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
Jack et al.
Brain 2010;133:3336-3348.
ABSTRACT | FULL TEXT  

Correlation of brain amyloid with "aerobic glycolysis": A question of assumptions?
Phelps and Barrio
Proc. Natl. Acad. Sci. USA 2010;107:17459-17460.
FULL TEXT  

Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia
Kadir and Nordberg
JNM 2010;51:1418-1430.
ABSTRACT | FULL TEXT  

Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia
Hu et al.
Neurology 2010;75:595-602.
ABSTRACT | FULL TEXT  

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden
Rabinovici et al.
Brain 2010;133:512-528.
ABSTRACT | FULL TEXT  

Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-{beta} Peptide Deposition Identified With Pittsburgh Compound B: Cognitive Decline Associated With A{beta} Deposition
Storandt et al.
Arch Neurol 2009;66:1476-1481.
ABSTRACT | FULL TEXT  

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
Villemagne et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:998-1001.
ABSTRACT | FULL TEXT  

Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease
Nelissen et al.
JNM 2009;50:1251-1259.
ABSTRACT | FULL TEXT  

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Jack et al.
Brain 2009;132:1355-1365.
ABSTRACT | FULL TEXT  

Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist
Klunk
Arch Neurol 2008;65:1281-1283.
FULL TEXT